加载中
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$1.75
−US$0.25 · -12.50%
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
前收盘价
US$1.75
−US$0.25 · -12.50%
盘后
US$1.85
+US$0.10 · +5.71%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
日内区间
当前US$1.75
52周区间
当前US$1.75
盘中时间采用ET。市场数据可能有所延迟。
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
日内区间
当前US$1.75
52周区间
当前US$1.75
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 229.33万 USD | 162.91万 USD | 107.2万 USD | 120.62万 USD | 117.97万 USD |
| 销货成本 | 87.24万 USD | 54.49万 USD | 38.01万 USD | 44.19万 USD | 37.04万 USD |
| 毛利 | 142.09万 USD | 108.42万 USD | 69.19万 USD | 76.43万 USD | 80.93万 USD |
| 研究与开发 | 757.77万 USD | 821.65万 USD | 720.87万 USD | 581.38万 USD | 408.43万 USD |
| 销售、一般及管理费用 | 1108.98万 USD | 1035.61万 USD | 750.81万 USD | 598.96万 USD | 447.07万 USD |
| 营业费用 | 1900.96万 USD | 1887万 USD | 1520.03万 USD | 1236.45万 USD | 914.61万 USD |
| 利息收入 | 10.18万 USD | 58.24万 USD | 43.1万 USD | 22.82万 USD | 3768 USD |
| 利息支出 | 189.11万 USD | 160.36万 USD | 16.54万 USD | 1.35万 USD | 1.92万 USD |
| 折旧和摊销 | 85.04万 USD | 87.2万 USD | 90.8万 USD | 88.91万 USD | 96.43万 USD |
| 营业利润 | −1758.87万 USD | −1778.58万 USD | −1450.84万 USD | −1160.03万 USD | −833.68万 USD |
| 净利润 | −1862.79万 USD | −1881.66万 USD | −1424.71万 USD | −1139.42万 USD | −753.78万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
